COVID “Treatment” is About to Get Interesting

Check this out. What you will see is a write-up that is interesting in several different ways. First, as the writer tells the story, the interest surrounding Molnupiravir, Merck’s much anticipated therapy for COVID-19, has captured analysts’ focus far more than the overall quarterly performance of the giant drug company. How those two factor will converge in quarters to come will be fascinating to watch.

Second, intervention decisions related to COVID-19 will get more complicated, and thus more interesting, when this product is approved. Sure, frontline for the foreseeable future will remain the vaccines. Molnupiravir’s role would seem fairly straightforward, i.e., in the treatment of compromised patients with mild to moderate disease. BUT. The possibility of using the product for postexposure prophylactic therapy could substantially increase the patient pool. 

And where will the monoclonal antibodies fit in as all of this gels? And what other forms of therapy will become available that will need to find their way into the mix?

Bottom Line. The general take on the situation is that COVID-19 and its variants will be around for a long, long time. Expect that the armamentarium of agents available to prevent and to fight the infection will continue to evolve. And for the developing pathways through that armamentarium to have a substantial impact on the economic fortunes of the companies that develop and market them. 

Leave a Reply

Your email address will not be published. Required fields are marked *